 |
|
|
| |
DORAVIRINE IS NON-INFERIOR TO DARUNAVIR+RITONAVIR IN PHASE 3 TREATMENT-NAÏVE TRIAL AT WEEK 48
|
| |
| |
Reported by Jules Levin
CROI 2017 Feb 14-17 Seattle, WA
Jean-Michel Molina1, Kathleen Squires2, Paul Sax3, Pedro Cahn4, Johan Lombaard5, Edwin DeJesus6, Xia Xu7, Bach-Yen Nguyen7, George Hanna7, and Carey Hwang7 for the DRIVE-FORWARD Study Team
1 University of Paris 7 and Hôpital Saint-Louis, Paris, France; 2 Thomas Jefferson University, Philadelphia, PA; 3 Brigham & Women’s Hospital, Harvard Medical School, Boston, MA;
4 Fundación Huesped, Buenos Aires, Argentina; 5 Josha Research, Bloemfontein, South Africa;
6 Orlando Immunology Center, Orlando, FL; 7 Merck & Co., Inc., Kenilworth NJ, USA
|
| |
|
|
|
|
|
